Metabolic Health, Insulin, and Breast Cancer: Why Oncologists Should Care About Insulin

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2020 Mar 11

PMID 32153503

Citations 42

Authors

Lisa D Yee

Joanne E Mortimer

Rama Natarajan

Eric C Dietze

Victoria L Seewaldt

Affiliations

Soon will be listed here.

Abstract

Studies investigating the potential link between adult pre-menopausal obesity [as measured by body mass index (BMI)] and triple-negative breast cancer have been inconsistent. Recent studies show that BMI is not an exact measure of metabolic health; individuals can be obese (BMI > 30 kg/m) and metabolically healthy or lean (BMI < 25 kg/m) and metabolically unhealthy. Consequently, there is a need to better understand the molecular signaling pathways that might be activated in individuals that are metabolically unhealthy and how these signaling pathways may drive biologically aggressive breast cancer. One key driver of both type-2 diabetes and cancer is insulin. Insulin is a potent hormone that activates many pathways that drive aggressive breast cancer biology. Here, we review (1) the controversial relationship between obesity and breast cancer, (2) the impact of insulin on organs, subcellular components, and cancer processes, (3) the potential link between insulin-signaling and cancer, and (4) consider time points during breast cancer prevention and treatment where insulin-signaling could be better controlled, with the ultimate goal of improving overall health, optimizing breast cancer prevention, and improving breast cancer survival.

Citing Articles

Identification of significant single-nucleotide polymorphisms associated with breast cancer recurrence and metastasis using GWAS.

Sun S, Yin S, Huang J, Zhou D, Tan Q, Man X Cancer Innov. 2025; 4(1):e142.

PMID: 39777116 PMC: 11705446. DOI: 10.1002/cai2.142.

Investigating the relationship between insulin use and all-cause mortality, breast cancer mortality, and recurrence risk in diabetic patients with breast cancer: A comprehensive systematic review and meta-analysis.

Loktionova M, Mohammadian M, Choopani R, Kheiri S, Mohammadian-Hafshejani A PLoS One. 2024; 19(12):e0314565.

PMID: 39636922 PMC: 11620406. DOI: 10.1371/journal.pone.0314565.

Anti-Hyperglycemic Effects of Thai Herbal Medicines.

Bunyakitcharoen A, Taychaworaditsakul W, Sireeratawong S, Chansakaow S Plants (Basel). 2024; 13(20).

PMID: 39458809 PMC: 11511234. DOI: 10.3390/plants13202862.

Insulin Resistance in Women Correlates with Chromatin Histone Lysine Acetylation, Inflammatory Signaling, and Accelerated Aging.

Vidal C, Alva-Ornelas J, Chen N, Senapati P, Tomsic J, Robles V Cancers (Basel). 2024; 16(15).

PMID: 39123463 PMC: 11311683. DOI: 10.3390/cancers16152735.

Exploring the multifaceted role of obesity in breast cancer progression.

Kakkat S, Suman P, Turbat-Herrera E, Singh S, Chakroborty D, Sarkar C Front Cell Dev Biol. 2024; 12():1408844.

PMID: 39040042 PMC: 11260727. DOI: 10.3389/fcell.2024.1408844.

References

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View

Dietze E, Chavez T, Seewaldt V . Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology. Am J Pathol. 2017; 188(2):280-290. PMC: 5785535. DOI: 10.1016/j.ajpath.2017.09.018. View

Guinan E, Connolly E, Kennedy M, Hussey J . The presentation of metabolic dysfunction and the relationship with energy output in breast cancer survivors: a cross-sectional study. Nutr J. 2013; 12:99. PMC: 3717288. DOI: 10.1186/1475-2891-12-99. View

Kendall D, Cuddihy R, Bergenstal R . Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Eur J Intern Med. 2009; 20 Suppl 2:S329-39. DOI: 10.1016/j.ejim.2009.05.009. View

Leibowitz G, Kaiser N, Cerasi E . β-Cell failure in type 2 diabetes. J Diabetes Investig. 2014; 2(2):82-91. PMC: 4015541. DOI: 10.1111/j.2040-1124.2010.00094.x. View

Vona-Davis L, Rose D, Hazard H, Howard-McNatt M, Adkins F, Partin J . Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev. 2008; 17(12):3319-24. PMC: 4665096. DOI: 10.1158/1055-9965.EPI-08-0544. View

. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403):157-63. DOI: 10.1016/S0140-6736(03)15268-3. View

Kumari S, Badana A, G M, G S, Malla R . Reactive Oxygen Species: A Key Constituent in Cancer Survival. Biomark Insights. 2018; 13:1177271918755391. PMC: 5808965. DOI: 10.1177/1177271918755391. View

Li L, Zhao G, Shi Z, Qi L, Zhou L, Fu Z . The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett. 2016; 12(5):3045-3050. PMC: 5103898. DOI: 10.3892/ol.2016.5110. View

10.

Johnson T, Ermolieff J, Jirousek M . Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov. 2002; 1(9):696-709. DOI: 10.1038/nrd895. View

11.

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

12.

Ambrosone C, Ciupak G, Bandera E, Jandorf L, Bovbjerg D, Zirpoli G . Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American Women. J Oncol. 2009; 2009:871250. PMC: 2766507. DOI: 10.1155/2009/871250. View

13.

Colditz G, Frazier A . Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev. 1995; 4(5):567-71. View

14.

Velho S, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P . Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr. 2010; 64(10):1043-51. DOI: 10.1038/ejcn.2010.114. View

15.

Pickup J, Crook M . Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia. 1998; 41(10):1241-8. DOI: 10.1007/s001250051058. View

16.

Feinstein R, Kanety H, Papa M, Lunenfeld B, Karasik A . Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993; 268(35):26055-8. View

17.

Oh H, Boeke C, Tamimi R, Smith-Warner S, Wang M, Willett W . The interaction between early-life body size and physical activity on risk of breast cancer. Int J Cancer. 2014; 137(3):571-81. PMC: 4405425. DOI: 10.1002/ijc.29272. View

18.

Warner S, Libby P . Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol. 1989; 142(1):100-9. View

19.

Fukushima M, Suzuki H, Seino Y . Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004; 66 Suppl 1:S37-43. DOI: 10.1016/j.diabres.2003.11.024. View

20.

Sato H, Carvalho G, Sato T, Lattermann R, Matsukawa T, Schricker T . The association of preoperative glycemic control, intraoperative insulin sensitivity, and outcomes after cardiac surgery. J Clin Endocrinol Metab. 2010; 95(9):4338-44. DOI: 10.1210/jc.2010-0135. View